Abstract
In patients with advanced high-grade ovarian cancer, the modeled CA-125 ELIMination rate constant K (KELIM) calculated during first-line chemotherapy was associated with overall survival (OS) in 6 independent datasets. We aimed to assess KELIM prognostic and surrogate values in the GCIG mega-database (MAOV), an individual patient data meta-analysis of randomized trials conducted before the PARP-inhibitor era (Paoletti, 2020).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
